Multiple alignments and more detailed analyses of all sequences demonstrated that nearly half of the analyzed HCC patients harbored at least the heterozygous ‐1573C genotype in the TRAIL promoter and, thus, lacked the functional in silico GATA‐1‐binding site (Fig. 1C). This evidence concerns the gene GATA1 and hepatocellular carcinoma.